Clinical trial NCT04131907: Optilume™ BPH Catheter System in Men With Symptomatic BPH
Official title: A Prospective, Multicenter, Double Blind, Randomized, Clinical Study to Evaluate the Safety and Efficacy of the Optilume™ BPH Catheter System in Men With Symptomatic BPH
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Benign Prostatic Hyperplasia
Keywords: BPH, Drug Coated Balloon, DCB, prostate, LUTS, Optilume
Lead sponsor: Urotronic Inc.
Sponsor class: INDUSTRY
Collaborators: name: ClinLogix. LLC
First posted: 2019-10-18
Enrollment: 162
Sex: MALE
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Randomized study with a non-randomized, Pharmacokinetics arm. Subjects randomized to the Control arm are allowed to crossover to the Test arm if they meet the eligibility criteria after completing the 3-Month Follow-up Visit and prior to the close of the 12-Month visit window.

Up to 625 subjects will be enrolled (i.e. consented) in the study in order to identify 162 eligible subjects (147 randomized subjects and 15 Pharmacokinetic subjects)
Primary purpose: TREATMENT

Brief summary: PINNACLE is a prospective, multi-center, randomized control clinical trial to establish the safety and efficacy of the Optilume™ BPH Catheter System in the treatment of benign prostatic hyperplasia (BPH)

Detailed description: This is a prospective, multi-center, double blind, randomized controlled clinical trial in a 2:1 allocation of Test versus sham Control. In addition, a single arm of 15 non-randomized subjects will be added to study the Pharmacokinetics of the drug. The objectives of the study are to assess the efficacy of Optilume BPH Catheter System to alleviate LUTS believed to be secondary to BPH (LUTS/BPH) and to evaluate the safety of Optilume BPH Catheter System in the treatment of LUTS/BPH.

Eligibility criteria: Inclusion Criteria:

1. Male subject 50-80 years of age who has symptomatic BPH
2. International Prostate Symptom Score (IPSS) ≥ 13
3. Peak urinary flow rate (Qmax) ≥ 5 ml/sec and ≤ 12 ml/sec (with minimum voided volume of ≥ 150 ml)
4. Prostate volume 20 to 80 gm as determined by transrectal ultrasound (TRUS)
5. Prostatic urethral length ≥ 32 mm and ≤ 55 mm as determined by TRUS
6. History of inadequate response, contraindication, or refusal of BPH medical therapy
7. Able to complete the study protocol in the opinion of the investigator

Exclusion Criteria:

1. Unable or unwilling to sign the Informed Consent Form (ICF) and/or comply with all the follow-up requirements
2. Unwilling to abstain or use protected sex for the first 30 days post treatment
3. Unwilling to abstain from sexual intercourse or use a highly effective contraceptive for at least 6 months post-procedure
4. Presence of an artificial urinary sphincter or stent(s) in the urethra or prostate
5. Any prior minimally invasive intervention (e.g. TUNA, Balloon, Microwave, Rezūm, UroLift) or surgical intervention of the prostate
6. Prostate specific antigen (PSA) ≥ 10 ng/ml unless prostate cancer is ruled out by biopsy
7. Confirmed or suspected malignancy of prostate or bladder
8. Active or history of epididymitis within the past 3 months
9. Previous pelvic irradiation or pelvic trauma surgery
10. Active urinary tract infection (UTI) confirmed by culture
11. Bacterial prostatitis within the last 12 months
12. Non-bacterial prostatitis within the last 5 years
13. Visible or invisible hematuria (\> 4 Red Blood Cells (RBCs) per high power field) on 2 separate urine specimens within the last 3 months without a know contributing factor
14. Neurogenic bladder or sphincter abnormalities or neurological disorders that might affect bladder or sphincter function
15. History of urinary incontinence
16. Previous or current diagnosis of urethral strictures, bladder neck contracture or detrusor muscle spasms
17. Previous rectal surgery, other than hemorrhoidectomy
18. Use of antihistamines, anticonvulsants or antispasmodics within 1 week prior to baseline assessment unless there is documented evidence of stable dosing for at least 6 months
19. Use of antidepressants with adrenergic effects (i.e. duloxetine, imipramine and amitriptyline), long-acting anticholinergics (LAAC) for chronic obstructive pulmonary disease (COPD), or androgens within 2 weeks prior to baseline assessment unless there is documented evidence of stable dosing for at least 3 months prior to baseline assessment
20. Use of Luteinizing Hormone-Releasing Hormone (LHRH) analogs within 12 months prior to baseline assessment
21. Use of Type II 5-alpha reductase inhibitor \[e.g. finasteride (Proscar, Propecia)\] within 3 months of baseline assessment
22. Use of 5-alpha reductase inhibitor \[e.g. dutasteride (Avodart)\] within 6 months of baseline assessment
23. Use of estrogen or drugs producing androgen suppression unless there is documented evidence of stable dosing for at least 3 months prior to baseline assessment
24. Use of alpha blockers or daily dose PDE5 inhibitor (e.g. Cialis) within 2 weeks of baseline assessment
25. Use of warfarin or novel oral anti-coagulants \[e.g., apixaban (Eliquis), fondaparinux (Arixtra), rivaroxaban (Xarelto) or edoxaban (Savaysa)\], unless the medication is safely discontinued prior to the procedure and is not planned to be restarted for at least 5 days post-procedure
26. Use of anti-platelet medications (e.g., clopidogrel, aspirin) within 10 days prior to the procedure or planned use within 5 days post-procedure
27. History of hypersensitivity reactions to paclitaxel, on medication that may have negative interaction with paclitaxel, presence of solid tumor with a baseline neutrophil count of \<1500 cells/mm3 or AIDS-related Kaposi's sarcoma with baseline neutrophil count of \<1000 cells/mm3
28. Incidence of spontaneous urinary retention within 6 months prior to baseline assessment
29. Current post-void residual volume \> 300 ml or catheter dependent bladder drainage
30. Known poor detrusor muscle function (e.g. Qmax \< 5 ml/sec)
31. Current bladder or prostatic urethral stones
32. Biopsy of prostate within 40 days prior to procedure
33. History of cancer in non-genitourinary system which is not considered in complete remission (except basal cell or squamous cell carcinoma of the skin). A potential participant is considered in complete remission if there has been no evidence of cancer within five years
34. Current uncontrolled diabetes (i.e. hemoglobin A1c ≥ 8%)
35. History of clinically significant comorbidities or presence of unstable conditions \[e.g. cardiovascular, lung, renal (serum creatinine \> 2.0 mg/dl), hepatic, bleeding disorders or metabolic impairment\] that may confound the results of the study or have a risk to subject per investigator's opinion
36. Any cognitive disorder that interferes with or precludes direct and accurate communication with the study investigator regarding the study or affects the ability to complete the study quality of life questionnaires
37. Life expectancy \< 10 years
38. Anatomy (e.g. presence of false passage or size of meatus) is not suitable for treatment in this study
39. Significant median lobe component \[e.g. intravesical prostatic protrusion (IPP) \> 1 cm\]
40. Device that corresponds with the subject's prostate size is not available
41. Currently enrolled in or plan to enroll in another investigational clinical study for any disease except for observational only study
42. In the opinion of the investigator, it is not in the subject's best interest to participate in the study

Primary outcomes:
measure: Number of Participants With >30% Improvement in the International Prostate Symptom Score (IPSS)
timeFrame: 12 months
measure: Number of Participants With Major Device Related Serious Complications
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: Arkansas Urology
state: Arkansas
city: Golden
country: United States
facility: Colorado Clinical Research
state: Colorado
city: Daytona Beach
country: United States
facility: Advanced Urology Institute
state: Florida
city: Tampa
country: United States
facility: Florida Urology Partners
state: Florida
city: Lake Barrington
country: United States
facility: Comprehensive Urologic Care
state: Illinois
city: Shreveport
country: United States
facility: Regional Urology, LLC
state: Louisiana
city: Hanover
country: United States
facility: Chesapeake Urology Research Associates
state: Maryland
city: Towson
country: United States
facility: Chesapeake Urology Research Associates
state: Maryland
city: Las Vegas
country: United States
facility: Sheldon Freedman MD, Ltd
state: Nevada
city: Englewood
country: United States
facility: New Jersey Urology
state: New Jersey
city: Garden City
country: United States
facility: AccuMed Research Associates
state: New York
city: New York
country: United States
facility: Manhattan Medical Research Practice, PLLC
state: New York
city: New York
country: United States
facility: Weill Cornell Medical College
state: New York
city: Raleigh
country: United States
facility: Associated Urologists of NC
state: North Carolina
city: Myrtle Beach
country: United States
facility: Carolina Urologic Research Center
state: South Carolina
city: Austin
country: United States
facility: Urology Austin, PLLC
state: Texas
city: Austin
country: United States
facility: North Austin Urology
state: Texas
city: El Paso
country: United States
facility: Rio Grande Urology
state: Texas
city: Webster
country: United States
facility: Clear Lake Specialties
state: Texas
city: Toronto
country: Canada
facility: University Urology Associates
state: Ontario
city: Montreal
country: Canada
facility: University of Montreal Hospital Center (CHUM)
state: Quebec
Study officials:
affiliation: Mount Sinai Health System
name: Steven A Kaplan, MD
role: PRINCIPAL_INVESTIGATOR
References: